Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Hahn

Showing results (701-710 of 764) with videos related to

Pageof 77
Sort By:
Cell Reports|October 3, 2019
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven CancersRita Sulahian, Jason J Kwon, Katherine H Walsh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2014
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinomaMarkus Riester, Lillian Werner, Joaquim Bellmunt, et al.
Cell Reports|January 21, 2014
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell stateYakov Chudnovsky, Dohoon Kim, Siyuan Zheng, et al.
Scientific Reports|March 27, 2020
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanismNathan J Schauer, Xiaoxi Liu, Robert S Magin, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activityJason J Kwon, Julien Dilly, Shengwu Liu, et al.
The Journal of Clinical Investigation|June 3, 2011
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumorsLauren L C Marotta, Vanessa Almendro, Andriy Marusyk, et al.
Cancer Research|February 14, 2019
MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid TumorsThomas P Howard, Taylor E Arnoff, Melinda R Song, et al.
Nature Cancer|April 19, 2022
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancerDaniel P Bondeson, Brenton R Paolella, Adhana Asfaw, et al.
BMC Cancer|May 8, 2019
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)W J Koemans, R T van der Kaaij, H Boot, et al.
Cell Reports|November 21, 2019
CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate CancerJustin H Hwang, Ji-Heui Seo, Michael L Beshiri, et al.
Pageof 77

Showing results (701-710 of 764) with videos related to

Sort By:
Pageof 77
Cell Reports|October 3, 2019
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven CancersRita Sulahian, Jason J Kwon, Katherine H Walsh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2014
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinomaMarkus Riester, Lillian Werner, Joaquim Bellmunt, et al.
Cell Reports|January 21, 2014
ZFHX4 interacts with the NuRD core member CHD4 and regulates the glioblastoma tumor-initiating cell stateYakov Chudnovsky, Dohoon Kim, Siyuan Zheng, et al.
Scientific Reports|March 27, 2020
Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanismNathan J Schauer, Xiaoxi Liu, Robert S Magin, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activityJason J Kwon, Julien Dilly, Shengwu Liu, et al.
The Journal of Clinical Investigation|June 3, 2011
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumorsLauren L C Marotta, Vanessa Almendro, Andriy Marusyk, et al.
Cancer Research|February 14, 2019
MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid TumorsThomas P Howard, Taylor E Arnoff, Melinda R Song, et al.
Nature Cancer|April 19, 2022
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancerDaniel P Bondeson, Brenton R Paolella, Adhana Asfaw, et al.
BMC Cancer|May 8, 2019
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)W J Koemans, R T van der Kaaij, H Boot, et al.
Cell Reports|November 21, 2019
CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate CancerJustin H Hwang, Ji-Heui Seo, Michael L Beshiri, et al.
Pageof 77